U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Approval Year

Unknown
149124
Substance Class Protein
Created
by admin
on Tue Apr 01 20:37:44 GMT 2025
Edited
by admin
on Tue Apr 01 20:37:44 GMT 2025
Protein Type MONOCLONAL ANTIBODY CONJUGATE
Protein Sub Type IGG1
Sequence Origin HUMANIZED MOUSE
Sequence Type COMPLETE
Record UNII
V860J30J9N
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
LINTUZUMAB SATETRAXETAN AC-225
Common Name English
ACTINIUM (225AC) LINTUZUMAB SATETRAXETAN
INN  
Preferred Name English
HUM-195 AC-225
Common Name English
225AC-LINTUZUMAB
Common Name English
SGN-33 AC-225
Code English
ACTINIUM AC-225 LINTUZUMAB
Common Name English
225AC-HUM195
Common Name English
Actinium (225Ac) lintuzumab satetraxetan [WHO-DD]
Common Name English
actinium (²²?Ac) lintuzumab satetraxetan [INN]
Common Name English
LINTUZUMAB ACTINIUM AC-225
Common Name English
ACTIMAB-A
Brand Name English
ACTINIUM AC 225 LINTUZUMAB
Common Name English
ACTINIUM-225-LABELED HUMANIZED ANTI-CD33 MONOCLONAL ANTIBODY HUM195
Common Name English
Classification Tree Code System Code
EU-Orphan Drug EU/3/17/1871
Created by admin on Tue Apr 01 20:37:44 GMT 2025 , Edited by admin on Tue Apr 01 20:37:44 GMT 2025
FDA ORPHAN DRUG 451714
Created by admin on Tue Apr 01 20:37:44 GMT 2025 , Edited by admin on Tue Apr 01 20:37:44 GMT 2025
NCI_THESAURUS C1511
Created by admin on Tue Apr 01 20:37:44 GMT 2025 , Edited by admin on Tue Apr 01 20:37:44 GMT 2025
Code System Code Type Description
DRUG BANK
DB15053
Created by admin on Tue Apr 01 20:37:44 GMT 2025 , Edited by admin on Tue Apr 01 20:37:44 GMT 2025
PRIMARY
INN
11089
Created by admin on Tue Apr 01 20:37:44 GMT 2025 , Edited by admin on Tue Apr 01 20:37:44 GMT 2025
PRIMARY
SMS_ID
300000038098
Created by admin on Tue Apr 01 20:37:44 GMT 2025 , Edited by admin on Tue Apr 01 20:37:44 GMT 2025
PRIMARY
NCI_THESAURUS
C82414
Created by admin on Tue Apr 01 20:37:44 GMT 2025 , Edited by admin on Tue Apr 01 20:37:44 GMT 2025
PRIMARY
CAS
2209911-94-2
Created by admin on Tue Apr 01 20:37:44 GMT 2025 , Edited by admin on Tue Apr 01 20:37:44 GMT 2025
PRIMARY
FDA UNII
V860J30J9N
Created by admin on Tue Apr 01 20:37:44 GMT 2025 , Edited by admin on Tue Apr 01 20:37:44 GMT 2025
PRIMARY
From To
1_22 1_96
1_143 1_199
1_219 3_218
1_225 2_225
1_228 2_228
1_260 1_320
1_366 1_424
2_22 2_96
2_143 2_199
2_219 4_218
2_260 2_320
2_366 2_424
3_23 3_92
3_138 3_198
4_23 4_92
4_138 4_198
Glycosylation Type MAMMALIAN
Glycosylation Link Type Site
N 1_296
N 2_296
Related Record Type Details
MYELOID CELL SURFACE ANTIGEN CD33
TARGET -> INHIBITOR
Related Record Type Details
LINTUZUMAB SATETRAXETAN AC-225
ACTIVE MOIETY

Structural Modifications

Modification Type Location Site Location Type Residue Modified Extent Fragment Name Fragment Approval
AMINO ACID REMOVAL [1_446] [2_446] C-TERMINUS LYSINE K3Z4F929H6
AMINO ACID REPLACEMENT RESIDUE_SPECIFIC LYSINE Amount: ACTINIUM AC-225 SATETRAXETAN-LYSINE 7CH33J3KMY
Name Property Type Amount Referenced Substance Defining Parameters References
Molecular Formula CHEMICAL
MOL_WEIGHT:ESTIMATED CHEMICAL
NIH
NCATS
PRIVACY NOTICE
ACCESSIBILITY
DISCLAIMER
HHS VULNERABILITY DISCLOSURE
For language access assistance, contact the NCATS Public Information Officer
National Center for Advancing Translational Sciences (NCATS),
6701 Democracy Boulevard, Bethesda MD 20892-4874 • 301-594-8966